The ACE Inhibitors

March 30, 2020

The death rate in patients with multiple comorbid conditions of metabolic dysfunction is vastly greater than the general population.

Less than 12.2% of the US population does not have severe metabolic inflammation or metabolic dysfunction.

Profoundly, the very drug class that is the preferred for blood pressure management in metabolic syndrome, may dramatically increase Coronavirus attachment to the lung alveolar cells [by upregulating surface ACE receptors number] increasing attachment of the virus to the cell. You have to have sufficient attachment for the virus to be internalized into the cell and the protease to allow the RNA transmission.

Angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers in COVID-19